Skip to main content

Advertisement

Fig. 4 | Cancer & Metabolism

Fig. 4

From: Metabolomics of oncogene-specific metabolic reprogramming during breast cancer

Fig. 4

Metabolomic differences associated with Wnt1-initiated tumors. Metabolomics revealed significantly different eicosanoid and cysteine-methionine metabolites in Wnt1 tumors compared to other transgenic model tumors. a Eicosanoid metabolism. Left: the eicosanoid pathway, with colors indicating increased metabolite levels compared to at least three other tumor groups (red), decreased levels (green), no change (blue), or not detected (black). Right: Graphs of the quantification of eicosanoid precursors (AA) and some eicosanoids. Middle line of box plots indicates median of sample group. *P < 0.05, Welch’s t test. b Quantification of cysteine-methionine metabolism. CDO1 (black) converts cysteine to hypotaurine. *P < 0.05, Welch’s t test. Statistical comparisons were made between Wnt1 and every other sample group. Abbreviations: COX cyclooxygenase, LOX lysyl oxidase DHGLA dihomo-γ-linolenic acid, HETE hydroxyeicosatetraenoic acid, SAM S-adenosyl methionine, SAH S-adenosylhomocysteine, THF tetrahydrofolate, Cdo1 cysteine dioxygenase

Back to article page